Ensign Peak Advisors
EWTX icon

Ensign Peak Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Ensign Peak Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80,509
Closed -$2.15M – 1698
2024
Q4 		$2.15M Buy
+80,509
New +$2.56M ﹤0.01% 904
2022
Q2 		– Sell
-662,526
Closed -$6.43M – 2178
2022
Q1 		$6.43M Buy
+662,526
New +$8.53M 0.01% 522

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ensign Peak Advisors's EWTX Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 80,509 shares — an estimated $2.15M sold.

Ensign Peak Advisors first reported a position in EWTX in Q1 2022 and held it in 2 quarters. The position peaked at $6.43M in Q1 2022. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 80,509 Edgewise Therapeutics shares in Q1 2025, an estimated $2.15M.
  • Ensign Peak Advisors first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 2 quarters.
  • Ensign Peak Advisors's Edgewise Therapeutics position peaked at $6.43M in Q1 2022.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.